Laura K. Chico - Robert W. Baird & Co. Incorporated, Research Division
Recognizing it's early days for Kyprolis, curious, have you seen the move to subcutaneous VELCADE impact Kyprolis uptake or the mix maybe between VELCADE and Revlimid in the earlier lines of treatment?
Helen I. Torley
So our focus is obviously on promoting Kyprolis in our indicated population as a single agent. I think your other question is what is the use of VELCADE as subcutaneous, and I can say that the majority of the market is now using VELCADE as subcutaneous. But that is, given our indication, not impacting us. Before Kyprolis was approved, there was no standard of care for patients who previously have been treated with bortezomib and an IMiD and we're progressing. And so Kyprolis fills that unmet need today.